Drugs / Bictegravir/emtricitabine/tenofovir alafenamide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05122754 | Dec 2021 → Feb 2024 | HIV infectious disease | Shanghai Public Health Clinical Center | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bictegravir/emtricitabine/tenofovir alafenamide | “Bictegravir/emtricitabine/tenofovir alafenamide once daily, 1 tablet at a time, with or without food for 48 weeks.” NCT05122754 ↗ |